TSE:ATE

Antibe Therapeutics Stock Forecast, Price & News

C$4.44
-0.11 (-2.42 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
C$4.34
Now: C$4.44
C$4.59
50-Day Range
C$4.54
MA: C$4.97
C$5.44
52-Week Range
C$3.05
Now: C$4.44
C$8.90
Volume172,474 shs
Average Volume226,756 shs
Market CapitalizationC$202.05 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-905-5705103
Employees47
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$9.33 million
Cash FlowC$0.39 per share
Book ValueC$0.44 per share

Profitability

Miscellaneous

Market CapC$202.05 million
Next Earnings Date7/23/2021 (Estimated)
OptionableNot Optionable

Headlines

IIROC Trade Resumption - ATE
February 18, 2021 |  finance.yahoo.com
TMX Group, Antibe Therapeutics, C-Suite at The Open
November 26, 2020 |  finance.yahoo.com
Antibe Therapeutics to Present at Upcoming Conferences
August 31, 2020 |  markets.businessinsider.com
See More Headlines

MarketRank

Overall MarketRank

1.30 out of 5 stars

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
C$4.44
-0.11 (-2.42 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATE News and Ratings via Email

Sign-up to receive the latest news and ratings for ATE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Antibe Therapeutics (TSE:ATE) Frequently Asked Questions

Is Antibe Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Antibe Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Antibe Therapeutics stock.
View analyst ratings for Antibe Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Antibe Therapeutics?

Wall Street analysts have given Antibe Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Antibe Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Antibe Therapeutics' next earnings date?

Antibe Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, July 23rd 2021.
View our earnings forecast for Antibe Therapeutics
.

How were Antibe Therapeutics' earnings last quarter?

Antibe Therapeutics Inc. (TSE:ATE) announced its quarterly earnings results on Friday, February, 12th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.04. The firm had revenue of $2.79 million for the quarter, compared to the consensus estimate of $2.50 million.
View Antibe Therapeutics' earnings history
.

How has Antibe Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Antibe Therapeutics' stock was trading at C$0.56 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ATE shares have increased by 692.9% and is now trading at C$4.44.
View which stocks have been most impacted by COVID-19
.

Is Antibe Therapeutics a good dividend stock?

Antibe Therapeutics pays an annual dividend of C$0.05 per share and currently has a dividend yield of 0.00%.
View Antibe Therapeutics' dividend history.

What price target have analysts set for ATE?

2 Wall Street analysts have issued 1 year target prices for Antibe Therapeutics' shares. Their forecasts range from C$1.00 to C$14.50. On average, they anticipate Antibe Therapeutics' share price to reach C$7.75 in the next twelve months. This suggests a possible upside of 74.5% from the stock's current price.
View analysts' price targets for Antibe Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Antibe Therapeutics' key executives?

Antibe Therapeutics' management team includes the following people:
  • Mr. Daniel Marcel Legault, Pres, CEO, Sec. & Director (Age 63, Pay $311.22k)
  • Dr. John Lawrence Wallace M.B.A., M.Sc., MSc, Ph.D., MBA, Founder, Chief Scientific Officer & Director (Age 64, Pay $311.22k)
  • Mr. Alain Wilson M.B.A., MBA, Chief Financial Officer
  • Dr. David James Vaughan, Chief Devel. Officer (Age 71, Pay $229.82k)
  • Mr. Scott Curtis C.F.A., M.Eng, CFA, Exec. VP
  • Ms. Christina Cameron B.B.A., VP of Investor Relations
  • Mr. Philip Stern, VP of Communications
  • Dr. Joseph Stauffer, Chief Medical Officer (Age 55)

Who are some of Antibe Therapeutics' key competitors?

What is Antibe Therapeutics' stock symbol?

Antibe Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ATE."

How do I buy shares of Antibe Therapeutics?

Shares of ATE and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Antibe Therapeutics' stock price today?

One share of ATE stock can currently be purchased for approximately C$4.44.

How much money does Antibe Therapeutics make?

Antibe Therapeutics has a market capitalization of C$202.05 million and generates C$9.33 million in revenue each year.

How many employees does Antibe Therapeutics have?

Antibe Therapeutics employs 47 workers across the globe.

What is Antibe Therapeutics' official website?

The official website for Antibe Therapeutics is www.antibethera.com.

Where are Antibe Therapeutics' headquarters?

Antibe Therapeutics is headquartered at 15 Prince Arthur Ave, TORONTO, ON M5R 1B2, Canada.

How can I contact Antibe Therapeutics?

Antibe Therapeutics' mailing address is 15 Prince Arthur Ave, TORONTO, ON M5R 1B2, Canada. The company can be reached via phone at +1-905-5705103.


This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.